Email Updates

You are here

Home

26 JUNE 2020 VOLUME 22 ISSUE 25

Media Coverage

  • HIV Prevention Drug Roll-Out Delayed Over Coronavirus

    The planned NHS roll-out of HIV prevention drug pre-exposure prophylaxis (PrEP) has been delayed due to COVID-19. In March, the Government approved PrEP to become routinely available on the NHS in England and announced an extra £16m of funding for local authorities in 2020/21 to ensure availability for everyone who needs it.

    June 25, 2020
    PrEP
    Pulse

  • PrEP Is Highly Effective; How Can We Increase Adoption?

    Numerous studies have found that when taken consistently, preexposure prophylaxis (PrEP) is 99 percent effective in preventing sexually transmitted HIV in men who have sex with men (MSM), heterosexual men, and women. There are fewer data regarding the use of PrEP to prevent HIV in people who inject drugs, with just one study reporting efficacy of 74 percent-89 percent.

    June 25, 2020
    PrEP
    Medscape

  • How HIV/AIDS Changed the World

    In the early 1990s, at the end of every workday, Matshidiso Moeti would lock a notebook in her desk at Botswana’s ministry of health. Written inside were the names of Botswanans who had tested positive for hiv. The stigma of having the virus that causes aids meant there had to be the “deepest secrecy”, she recalls.

    June 25, 2020
    General
    The Economist

  • How to Include the Perspectives of Women Living With HIV in Research

    As the 23rd international AIDS conference nears, we reflect once more on what it takes to ensure that issues facing women living with HIV are adequately addressed, especially in the context of COVID-19 and increased rates of domestic violence globally. We know how violence increases women’s vulnerability to HIV by 1.5 and worsens its effects: but will the conference, and other authoritative institutions like journals, publishers, and funders, address this?

    June 25, 2020
    General
    BMJ Sexual and Reproductive Health Blog

  • Fight Against Malaria, TB and HIV Hit As Resources Diverted to COVID-19, Survey Shows

    The fight against malaria, HIV and TB has been severely disrupted by the coronavirus pandemic, risking a huge rise in the number of deaths and infections. A survey of the 106 countries where the Global Fund to Fight Aids, Tuberculosis and Malaria targets its budget found that nearly three quarters of programmes have been disrupted as a result of the pandemic.

    June 24, 2020
    General
    The Telegraph

  • Easier and Equitable Access to PrEP: How DSD Can Help Get Us There

    Improving access to HIV prevention is critical if we want to see meaningful reductions in new infections. Although the adoption and use of oral pre-exposure prophylaxis (PrEP) has gradually increased, with an estimated half a million people initiating PrEP worldwide, we are far from achieving the global target of three million users by the end of 2020.

    June 24, 2020
    PrEP
    Differentiated Service Delivery

  • First COVID-19 Vaccine Trial in Africa Will Include HIV Patients

    South Africa begins a coronavirus vaccine trial on Wednesday, the first such test on the continent, with its 2,000 volunteers planned to include some living with HIV.

    June 24, 2020
    General
    IOL

  • India Moving Forward in Fight Against HIV/AIDS

    Many years ago, a young gay man, who came regularly to the Naz Foundation (India) Trust, disappeared for several months. When he returned to Naz, he looked "absolutely shattered," Anjali Gopalan, founder and executive director of the foundation, recalled while sitting across from the Bay Area Reporter in her office in Delhi earlier this year.

    June 24, 2020
    General
    Bay Area Reporter

  • $14M Federal Grant to Research CAR-T Gene Therapy to Cure HIV

    A group of collaborating scientists received a $13.65 million federal grant to study and develop a CAR-T therapy that will genetically modify immune cells and potentially cure HIV, according to a press release from the University of California, Los Angeles (UCLA).

    June 23, 2020
    Cure
    POZ

  • New HIV Vaccine Booster Prompts Long-Lived Immune Response in Monkeys

    The finding could eventually be used to make an HIV vaccine prompt a longer-lasting immune response in humans. Researchers have developed a new HIV vaccine booster, or adjuvant, that helped give rise to an immune response in monkeys that lasted for up to 12 months in a recent study.

    June 23, 2020
    HIV Vaccine
    POZ

  • UN Warns of Risk of Low Distribution of AIDS Drug Amid COVID Lockdowns

    The COVID-19 pandemic could affect availability and distribution of antiretroviral medicine used to treat HIV, UNAIDS said Monday. A recent survey conducted by UNAIDS showed the impacts that lockdowns and border closures imposed to stop the spread of the coronavirus will impede supplying prescriptions, particularly to low- and middle-income countries.

    June 22, 2020
    Treatment
    Voice of America

  • HIV Drug Sped to Approval 25 Years Ago Revolutionized Fight Against AIDS

    AIDS activist Larry Kramer used to wear an oversized rectangular turquoise ring on his left finger, tinged with variations of green. A turquoise band circled a second finger. Two large turquoise rings decorated his other hand.

    June 22, 2020
    Treatment
    Voice of America

  • If the Government Cared About HIV, PrEP Would Be Free

    If you had the power to potentially stop the HIV epidemic in its tracks, would you use it? Not if you’re the US government—or a multibillion-dollar pharmaceutical giant.

    June 22, 2020
    PrEP
    Rewire

  • SA ‘Can’t Afford’ to Default on Three-in-One HIV Pill

    The fragile gains made in HIV-testing and antiretroviral regimens may be undone by the unintended consequences of the national COVID-19 lockdown says SANAC Civil Society Forum.

    June 22, 2020
    Treatment
    Health-E News

Published Research

Announcements